Zurcher Kantonalbank Zurich Cantonalbank Acquires 2,387 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 38.1% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 8,645 shares of the company’s stock after acquiring an additional 2,387 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in SpringWorks Therapeutics were worth $316,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. TD Asset Management Inc boosted its holdings in SpringWorks Therapeutics by 122.1% in the third quarter. TD Asset Management Inc now owns 138,832 shares of the company’s stock valued at $3,210,000 after acquiring an additional 76,316 shares during the last quarter. Assetmark Inc. lifted its holdings in SpringWorks Therapeutics by 15.6% in the third quarter. Assetmark Inc. now owns 10,814 shares of the company’s stock valued at $250,000 after buying an additional 1,461 shares during the period. Hennion & Walsh Asset Management Inc. boosted its position in SpringWorks Therapeutics by 7.8% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 33,260 shares of the company’s stock valued at $769,000 after acquiring an additional 2,400 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in SpringWorks Therapeutics by 96.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,612 shares of the company’s stock worth $37,000 after acquiring an additional 792 shares during the period. Finally, Teacher Retirement System of Texas raised its position in shares of SpringWorks Therapeutics by 4.7% in the 3rd quarter. Teacher Retirement System of Texas now owns 9,770 shares of the company’s stock worth $226,000 after acquiring an additional 441 shares in the last quarter.

Insider Activity at SpringWorks Therapeutics

In other SpringWorks Therapeutics news, insider Daniel Pichl sold 15,000 shares of SpringWorks Therapeutics stock in a transaction on Friday, February 16th. The shares were sold at an average price of $50.10, for a total transaction of $751,500.00. Following the transaction, the insider now directly owns 45,212 shares of the company’s stock, valued at approximately $2,265,121.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.61% of the stock is currently owned by insiders.

SpringWorks Therapeutics Trading Up 4.1 %

Shares of SWTX stock opened at $45.11 on Monday. The firm has a fifty day simple moving average of $47.21 and a two-hundred day simple moving average of $38.75. SpringWorks Therapeutics, Inc. has a 12 month low of $18.00 and a 12 month high of $53.92. The firm has a market capitalization of $3.33 billion, a PE ratio of -8.78 and a beta of 0.84.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($1.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.01). The business had revenue of $21.00 million during the quarter, compared to analyst estimates of $12.07 million. The business’s revenue was up 2000.0% on a year-over-year basis. During the same period in the prior year, the business earned ($1.18) EPS. On average, equities analysts predict that SpringWorks Therapeutics, Inc. will post -4.75 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on SWTX shares. Barclays raised their target price on SpringWorks Therapeutics from $47.00 to $63.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. JPMorgan Chase & Co. raised their price objective on shares of SpringWorks Therapeutics from $73.00 to $74.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. HC Wainwright boosted their target price on shares of SpringWorks Therapeutics from $73.00 to $74.00 and gave the company a “buy” rating in a research report on Wednesday, March 6th. Guggenheim initiated coverage on shares of SpringWorks Therapeutics in a report on Monday, February 5th. They issued a “buy” rating and a $75.00 price target for the company. Finally, Wedbush reiterated an “outperform” rating and set a $75.00 price objective (up previously from $70.00) on shares of SpringWorks Therapeutics in a report on Thursday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, SpringWorks Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $68.83.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.